Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

The University of Chicago

Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?

The University of Chicago via Independent

Go to class Write review
DataCamp Ad

AI Engineer - Learn how to integrate AI into software applications

Learn More → Great Learning Ad

Advanced Techniques in Data Visualization - Self Paced Online

Learn More →

Overview

Google, IBM & Meta Certificates — All 10,000+ Courses at 40% Off
One annual plan covers every course and certificate on Coursera. 40% off for a limited time.
Get Full Access
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody drug conjugates (ADCs) therapy may play a role. Educational Partner: The Academy for Continued Healthcare Learning (ACHL) Medium: Online Presentation Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc. Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

Syllabus

At the conclusion of this activity, participants will be able to:

  • Discuss new targeted treatment approaches in the setting of TNBC;
  • Discuss the role of ADC therapies and TROP2 for triple-negative breast cancer.

Tags

Reviews

Start your review of Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?

Go to class

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Sign up for free
Someone learning on their laptop while sitting on the floor.